Pfizer Recalls LEVOXYL 200 mcg Tablets Due to Superpotent Risk
Pfizer recalls LEVOXYL 200 mcg tablets (100-count) for superpotent risk. This may cause overmedication if taken without medical supervision.
Use caution until it’s fixed
Superpotent
Contact the company
What happened, in plain English
Pfizer has recalled LEVOXYL 200 mcg tablets (100-count) because they are superpotent, meaning they could cause overmedication if taken without medical supervision. This is a serious risk for people who take thyroid medication without proper guidance. Read more at govinfonow.com/recall/42259-pfizer-recalls-levoxyl-200-mcg-tablets-due-to-superpotent-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/42259-pfizer-recalls-levoxyl-200-mcg-tablets-due-to-superpotent-risk · Updated October 9, 2026 · FDA enforcement record: FDA #D-0150-2017
Cite this page
“Pfizer Recalls LEVOXYL 200 mcg Tablets Due to Superpotent Risk.” GovInfoNow, updated October 9, 2026. https://govinfonow.com/recall/42259-pfizer-recalls-levoxyl-200-mcg-tablets-due-to-superpotent-risk. Based on FDA recall #D-0150-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0150-2017%22&limit=1).
Why it’s dangerous
The tablets are superpotent, meaning they contain a higher dose than standard. If taken without medical supervision, this could lead to overmedication, causing symptoms like rapid heartbeat, anxiety, or other thyroid-related issues.
Who’s affected
People who have a prescription for LEVOXYL 200 mcg tablets (100-count) from King Pharmaceuticals, Inc. in Bristol, TN. Those who take thyroid medication without medical supervision are at higher risk.
How to tell if you have this one
Check for LEVOXYL(R) 200 mcg tablets in 100-count bottles with NDC 60793-860-01, manufactured by King Pharmaceuticals, Inc. in Bristol, TN, and expiring 08/2017.
- Brand
Pfizer- Category
Drug
What to do — step by step
Check Your Prescription
Verify if you have a prescription for LEVOXYL 200 mcg tablets (100-count) from King Pharmaceuticals, Inc. in Bristol, TN.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 3.5 years after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0150-2017 (November 7, 2016) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0150-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 9, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.